|
JPS4935635B1
(enExample)
|
1970-12-28 |
1974-09-25 |
|
|
|
CH563405A5
(enExample)
|
1971-09-10 |
1975-06-30 |
Duschinsky Robert Dr Schweiz I |
|
|
DE2226295A1
(de)
|
1972-05-30 |
1973-12-20 |
Henning Berlin Gmbh |
Salpetersaeureester von purinnucleosiden und verfahren zur herstellung derselben
|
|
DE2342479A1
(de)
|
1973-08-23 |
1975-03-13 |
Merck Patent Gmbh |
Ribonucleosid-5'-nitrate und verfahren zu ihrer herstellung
|
|
GB2001976B
(en)
|
1977-08-03 |
1982-03-10 |
Yamasa Shoyu Kk |
S-adenosyl-l-methionine compositions and production thereof
|
|
US4849311A
(en)
|
1986-09-24 |
1989-07-18 |
Toa Nenryo Kogyo Kabushiki Kaisha |
Immobilized electrolyte membrane
|
|
US4968697A
(en)
|
1987-02-04 |
1990-11-06 |
Ciba-Geigy Corporation |
2-substituted adenosine 5'-carboxamides as antihypertensive agents
|
|
US5219840A
(en)
|
1987-04-06 |
1993-06-15 |
Sandoz Ltd. |
Antihypertensive 9-(2,N6 -disubstituted adenyl) ribofuranuronic acid derivatives
|
|
US5591887A
(en)
|
1987-04-30 |
1997-01-07 |
R-Tech Ueno, Ltd. |
Prostaglandins of the F series
|
|
US5221763A
(en)
|
1987-04-30 |
1993-06-22 |
R-Tech Ueno, Ltd. |
Prostaglandins of the F series
|
|
EP0569046B1
(en)
|
1988-09-06 |
2002-11-13 |
Pharmacia Aktiebolag |
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
|
|
US6187813B1
(en)
|
1990-04-10 |
2001-02-13 |
Pharmacia & Upjohn Aktiebolag |
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
|
|
US5296504A
(en)
|
1988-09-06 |
1994-03-22 |
Kabi Pharmacia |
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
|
|
US5140015A
(en)
|
1990-02-20 |
1992-08-18 |
Whitby Research, Inc. |
2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
|
|
US5280015A
(en)
|
1990-09-05 |
1994-01-18 |
The United States Of America As Represented By The Department Of Health And Human Services |
2-substituted adenosines and 2-substituted adenosine 5'-carboxamides
|
|
JP3020580B2
(ja)
|
1990-09-28 |
2000-03-15 |
株式会社日立製作所 |
マイクロ波プラズマ処理装置
|
|
US5206222A
(en)
|
1991-05-22 |
1993-04-27 |
Vanderbilt University |
Methods for the reduction of myocardial reperfusion injury
|
|
HU212570B
(en)
|
1991-06-24 |
1996-08-29 |
Chinoin Gyogyszer Es Vegyeszet |
Process for producing 13,14-dihydro-15(r)-17-phenyl-18,19,20-trinor-pgf2alfa-isopropylester
|
|
US5407793A
(en)
|
1991-10-18 |
1995-04-18 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
An aqueous heart preservation and cardioplegia solution
|
|
US5278150A
(en)
|
1992-04-24 |
1994-01-11 |
Whitby Research, Inc. |
2-hydrazoadenosines and their utility for the treatmeat of vascular conditions
|
|
DK62692D0
(enExample)
|
1992-05-14 |
1992-05-14 |
Novo Nordisk As |
|
|
WO1994002497A1
(en)
|
1992-07-15 |
1994-02-03 |
The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Sulfo-derivatives of adenosine
|
|
US5972991A
(en)
|
1992-09-21 |
1999-10-26 |
Allergan |
Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
|
|
US5338430A
(en)
|
1992-12-23 |
1994-08-16 |
Minnesota Mining And Manufacturing Company |
Nanostructured electrode membranes
|
|
US5443836A
(en)
|
1993-03-15 |
1995-08-22 |
Gensia, Inc. |
Methods for protecting tissues and organs from ischemic damage
|
|
ATE206432T1
(de)
|
1993-07-13 |
2001-10-15 |
Nasa |
A3 -adenosin -rezeptor agonisten
|
|
US5589467A
(en)
|
1993-09-17 |
1996-12-31 |
Novo Nordisk A/S |
2,5',N6-trisubstituted adenosine derivatives
|
|
WO1995011681A1
(en)
|
1993-10-29 |
1995-05-04 |
Merck & Co., Inc. |
Human adenosine receptor antagonists
|
|
US5620676A
(en)
|
1994-03-08 |
1997-04-15 |
The United States Of America As Represented By The Department Of Health And Human Services |
Biologically active ATP analogs
|
|
EP0704215A3
(en)
|
1994-06-02 |
1998-04-01 |
Takeda Chemical Industries, Ltd. |
Inhibitor of vascular permeability enhancer
|
|
GB9414193D0
(en)
|
1994-07-14 |
1994-08-31 |
Glaxo Group Ltd |
Compounds
|
|
US5801159A
(en)
|
1996-02-23 |
1998-09-01 |
Galileo Laboratories, Inc. |
Method and composition for inhibiting cellular irreversible changes due to stress
|
|
CN1164122A
(zh)
|
1996-03-01 |
1997-11-05 |
株式会社日立制作所 |
等离子处理机及其处理方法
|
|
AU2022497A
(en)
|
1996-03-13 |
1997-10-01 |
Novo Nordisk A/S |
A method of treating disorders related to cytokines in mammals
|
|
WO1997033879A1
(en)
|
1996-03-15 |
1997-09-18 |
Merck & Co., Inc. |
Compounds and methods for selectively inhibiting activation of the human a3 adenosine receptor
|
|
US5789416B1
(en)
|
1996-08-27 |
1999-10-05 |
Cv Therapeutics Inc |
N6 mono heterocyclic substituted adenosine derivatives
|
|
TW528755B
(en)
|
1996-12-24 |
2003-04-21 |
Glaxo Group Ltd |
2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
|
|
CA2289731A1
(en)
|
1997-05-09 |
1998-11-12 |
The United States Of America, Represented By The Secretary, Department O F Health And Human Services |
Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
|
|
JP2001519386A
(ja)
|
1997-10-15 |
2001-10-23 |
トーマス・ジェファーソン・ユニバーシティ |
哺乳動物における血管収縮または血管痙攣を予防または緩和するための一酸化窒素供与体組成物、方法、装置およびキット
|
|
AU1363699A
(en)
|
1997-10-23 |
1999-05-10 |
National Institute Of Health |
Methods for reducing ischemic injury of the heart via the sequential administ ration of monophosphoryl lipid a and adenosine receptor agents
|
|
GB9723566D0
(en)
|
1997-11-08 |
1998-01-07 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB9723590D0
(en)
|
1997-11-08 |
1998-01-07 |
Glaxo Group Ltd |
Chemical compounds
|
|
FR2775901B1
(fr)
|
1998-03-13 |
2000-07-21 |
Logeais Labor Jacques |
Sels de cetoacides et de derives amines, et leur utilisation pour la preparation de medicaments
|
|
GB9813535D0
(en)
|
1998-06-23 |
1998-08-19 |
Glaxo Group Ltd |
Chemical compounds
|
|
CA2337499A1
(en)
|
1998-07-16 |
2000-01-27 |
The Trustees Of The University Of Pennsylvania |
Methods for reducing intraocular pressure using a3-adenosine antagonists
|
|
EP1121372B1
(en)
|
1998-10-16 |
2006-06-28 |
Pfizer Limited |
Adenine derivatives
|
|
IL127947A0
(en)
|
1999-01-07 |
1999-11-30 |
Can Fite Technologies Ltd |
Pharmaceutical use of adenosine agonists
|
|
US6232297B1
(en)
|
1999-02-01 |
2001-05-15 |
University Of Virginia Patent Foundation |
Methods and compositions for treating inflammatory response
|
|
US6403567B1
(en)
|
1999-06-22 |
2002-06-11 |
Cv Therapeutics, Inc. |
N-pyrazole A2A adenosine receptor agonists
|
|
US6180615B1
(en)
|
1999-06-22 |
2001-01-30 |
Cv Therapeutics, Inc. |
Propargyl phenyl ether A2A receptor agonists
|
|
US6214807B1
(en)
|
1999-06-22 |
2001-04-10 |
Cv Therapeutics, Inc. |
C-pyrazole 2A A receptor agonists
|
|
JP2003502434A
(ja)
|
1999-06-22 |
2003-01-21 |
スィーヴィー セラピューティクス インコーポレイテッド |
チオフェンa2a受容体アゴニスト
|
|
IL133680A0
(en)
|
1999-09-10 |
2001-04-30 |
Can Fite Technologies Ltd |
Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
|
|
GB9924361D0
(en)
|
1999-10-14 |
1999-12-15 |
Pfizer Ltd |
Purine derivatives
|
|
US6368573B1
(en)
|
1999-11-15 |
2002-04-09 |
King Pharmaceuticals Research And Development, Inc. |
Diagnostic uses of 2-substituted adenosine carboxamides
|
|
US6258793B1
(en)
|
1999-12-03 |
2001-07-10 |
Cv Therapeutics, Inc. |
N6 heterocyclic 5′ modified adenosine derivatives
|
|
GB9930071D0
(en)
|
1999-12-20 |
2000-02-09 |
Glaxo Group Ltd |
Medicaments
|
|
GB0003960D0
(en)
|
2000-02-18 |
2000-04-12 |
Pfizer Ltd |
Purine derivatives
|
|
US20010051612A1
(en)
|
2000-02-23 |
2001-12-13 |
Gloria Cristalli |
2-Thioether A2A receptor agonists
|
|
US20030010454A1
(en)
|
2000-03-27 |
2003-01-16 |
Bailey Andrew D. |
Method and apparatus for varying a magnetic field to control a volume of a plasma
|
|
US6534651B2
(en)
|
2000-04-06 |
2003-03-18 |
Inotek Pharmaceuticals Corp. |
7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
|
|
US6753322B2
(en)
|
2000-06-06 |
2004-06-22 |
Pfizer Inc |
2-aminocarbonyl-9H-purine derivatives
|
|
US6921753B2
(en)
|
2000-06-27 |
2005-07-26 |
Pfizer Inc |
Purine derivatives
|
|
CN1450896A
(zh)
|
2000-07-28 |
2003-10-22 |
印斯拜尔药品股份有限公司 |
用吲哚衍生物降低眼内压的方法
|
|
BR0206492A
(pt)
|
2001-01-16 |
2004-02-10 |
Can Fite Biopharma Ltd |
Composição farmacêutica para inibir a replicação de um vìrus dentro de células, uso de pelo menos um agonista receptor de adenosina a3, e, métodos para inibir a replicação de um vìrus em células
|
|
GB2372742A
(en)
|
2001-03-03 |
2002-09-04 |
Univ Leiden |
C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses
|
|
EP1241176A1
(en)
|
2001-03-16 |
2002-09-18 |
Pfizer Products Inc. |
Purine derivatives for the treatment of ischemia
|
|
US20040204481A1
(en)
|
2001-04-12 |
2004-10-14 |
Pnina Fishman |
Activation of natural killer cells by adenosine A3 receptor agonists
|
|
US20030013675A1
(en)
|
2001-05-25 |
2003-01-16 |
Boehringer Ingelheim Pharma Kg |
Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases
|
|
US7713946B2
(en)
|
2002-07-11 |
2010-05-11 |
Cv Therapeutics, Inc. |
Partial and full agonists A1 adenosine receptors
|
|
JP2004537401A
(ja)
|
2001-08-08 |
2004-12-16 |
ブラウン ユニバーシティ リサーチ ファウンデーション |
疎水性薬物の微粉砕方法
|
|
CA2460911C
(en)
|
2001-10-01 |
2011-08-30 |
University Of Virginia Patent Foundation |
2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
|
|
NZ536001A
(en)
|
2002-04-18 |
2006-05-26 |
Cv Therapeutics Inc |
Method of treating arrhythmias comprising administration of an A1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside
|
|
MXPA04009471A
(es)
|
2002-04-30 |
2005-01-25 |
Alcon Inc |
Agentes que regulan, inhiben o modulan la actividad y/o expresion de factor de crecimiento de tejido de conexion (ctgf) como un medio unico para ambos reducir la presion intraocular y tratar retinopatias glaucomatosas/neuropatias opticas.
|
|
GB0216416D0
(en)
|
2002-07-15 |
2002-08-21 |
Novartis Ag |
Organic compounds
|
|
US20030139427A1
(en)
*
|
2002-08-23 |
2003-07-24 |
Osi Pharmaceuticals Inc. |
Bicyclic pyrimidinyl derivatives and methods of use thereof
|
|
WO2004056180A1
(en)
|
2002-12-23 |
2004-07-08 |
Global Cardiac Solutions Pty Ltd |
Organ preconditioning, arrest, protection, preservation and recovery (1)
|
|
GB2436255B
(en)
|
2002-12-23 |
2007-11-28 |
Global Cardiac Solutions Pty L |
Organ preconditioning, arrest, protection, preservation and recovery
|
|
CA2468664C
(en)
|
2003-06-03 |
2012-03-06 |
Allergan, Inc. |
Ketorolac tromethamine compositions for treating or preventing ocular pain
|
|
EP1718286A4
(en)
|
2004-01-22 |
2010-03-31 |
Nicox Sa |
NITROSIS AND / OR NITROSYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
|
|
PT1758596E
(pt)
|
2004-05-26 |
2010-06-23 |
Inotek Pharmaceuticals Corp |
Derivados de purina como agonistas do receptor de adenosina a1 e processos para a sua utilização
|
|
CN101010085B
(zh)
|
2004-05-26 |
2012-12-26 |
伊诺泰克制药公司 |
嘌呤衍生物作为腺苷a1受体激动剂及其用法
|
|
CA2573682A1
(en)
|
2004-07-12 |
2006-02-16 |
Cv Therapeutics, Inc. |
Process for the preparation of a1 adenosine receptor agonists
|
|
US20090220516A1
(en)
|
2005-06-22 |
2009-09-03 |
Alan Laties |
Neuroprotection of retinal ganglion cells
|
|
AU2006320578B2
(en)
*
|
2005-11-30 |
2013-01-31 |
Inotek Pharmaceuticals Corporation |
Purine derivatives and methods of use thereof
|
|
WO2008029276A2
(en)
|
2006-02-02 |
2008-03-13 |
Allergan, Inc. |
Compositions and methods for the treatment of ophthalmic disease
|
|
US8784886B2
(en)
|
2006-03-09 |
2014-07-22 |
GlaxoSmithKline, LLC |
Coating capsules with active pharmaceutical ingredients
|
|
JP2009530393A
(ja)
|
2006-03-23 |
2009-08-27 |
イノテック ファーマシューティカルズ コーポレイション |
プリン化合物およびその使用方法
|
|
US8163737B2
(en)
|
2006-06-13 |
2012-04-24 |
Vertex Pharmaceuticals Incorporated |
CGRP receptor antagonists
|
|
WO2008011836A2
(es)
|
2006-07-25 |
2008-01-31 |
Osmotica Corp. |
Soluciones oftálmicas
|
|
EP2076267A4
(en)
*
|
2006-10-06 |
2013-07-31 |
Univ Pennsylvania |
EFFECTIVE DELIVERY OF CROSS SPECIES A3 ADENOSINE RECEPTOR ANTAGONISTS TO REDUCE AUGENIN PRESSURE
|
|
ATE513470T1
(de)
|
2006-11-10 |
2011-07-15 |
Basf Se |
Kristalline fipronil-modifikation
|
|
CA2671613C
(en)
|
2006-12-05 |
2018-07-03 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
Methods of use of trk receptor modulators
|
|
JP2008266143A
(ja)
|
2007-04-16 |
2008-11-06 |
Santen Pharmaceut Co Ltd |
アデノシン誘導体を有効成分として含有する緑内障治療剤
|
|
EP2205071B1
(en)
|
2007-10-11 |
2015-07-22 |
Biogen MA Inc. |
Lingo-1 antagonists and trkb agonists for use in the treatment of glaucoma
|
|
WO2009076580A2
(en)
|
2007-12-12 |
2009-06-18 |
Thomas Jefferson University |
Compositions and methods for the treatment and prevention of cardiovascular diseases
|
|
JP2011511802A
(ja)
|
2008-02-07 |
2011-04-14 |
ギリアード・パロ・アルト・インコーポレイテッド |
Abca−1を上昇させる化合物およびかかる化合物の使用方法
|
|
WO2010056981A2
(en)
|
2008-11-13 |
2010-05-20 |
Massachusetts General Hospital |
Methods and compositions for regulating iron homeostasis by modulation bmp-6
|
|
KR101757940B1
(ko)
|
2009-05-01 |
2017-07-13 |
이노텍 파마슈티컬스 코포레이션 |
인간 안압을 감소시키는 방법
|
|
CN102665730A
(zh)
*
|
2009-10-26 |
2012-09-12 |
伊诺泰克制药公司 |
眼用制剂及其制造方法
|
|
WO2011077435A1
(en)
|
2009-12-22 |
2011-06-30 |
Bar-Ilan University |
Compositions and methods for reducing intraocular pressure
|
|
BR112012017106A2
(pt)
|
2010-01-11 |
2018-05-29 |
Inotek Pharmaceuticals Corp |
combinação, kit e método de redução de pressão intraocular.
|
|
US20110217262A1
(en)
|
2010-03-05 |
2011-09-08 |
Kornfield Julia A |
Treatment of Ocular Surface Disorders by Increasing Conjunctival Vascular Permeability
|
|
HUE031529T2
(en)
*
|
2010-03-19 |
2017-07-28 |
Inotek Pharmaceuticals Corp |
Combination compositions of adenosine a1 agonists and carbonic anhydrase inhibitors for reducing intraocular pressure
|
|
JP2013522323A
(ja)
|
2010-03-19 |
2013-06-13 |
イノテック ファーマシューティカルズ コーポレイション |
眼内圧を下げるためのアデノシンA1受容体アゴニストと非選択的β−アドレナリン受容体遮断薬との組合せ組成物
|
|
SG184223A1
(en)
|
2010-03-26 |
2012-10-30 |
Inotek Pharmaceuticals Corp |
Adenosine compounds and their use thereof
|
|
JP2013523739A
(ja)
*
|
2010-03-26 |
2013-06-17 |
イノテック ファーマシューティカルズ コーポレイション |
N6−シクロペンチルアデノシン(cpa)、cpa誘導体またはそれらのプロドラッグを用いてヒトにおける眼内圧を低下させる方法
|
|
WO2013049725A2
(en)
|
2011-09-30 |
2013-04-04 |
Tufts University |
Methods of using adenosine a1 receptor activation for treating depression
|
|
NZ627778A
(en)
|
2012-01-26 |
2017-01-27 |
Inotek Pharmaceuticals Corp |
Anhydrous polymorphs of (2r,3s,4r,5r)-5-(6-(cyclopentylamino)-9h-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)} methyl nitrate and processes of preparation thereof
|
|
AU2014239222A1
(en)
*
|
2013-03-15 |
2015-10-01 |
Inotek Pharmaceuticals Corporation |
Ophthalmic formulations
|
|
CN105188713A
(zh)
|
2013-03-15 |
2015-12-23 |
伊诺泰克制药公司 |
提供眼部神经保护的方法
|